<DOC>
	<DOCNO>NCT02396953</DOCNO>
	<brief_summary>The objective protocol determine maximum tolerate dose investigate pharmacokinetics single dose lanreotide PRF subject acromegaly .</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose , Safety Tolerability Single Dose Lanreotide Prolonged Release Formulation ( PRF ) Subjects With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Documented diagnosis acromegaly . Provided write informed consent prior study related procedure . Between 18 75 year age inclusive . Female nonchildbearing potential male . Nonchildbearing potential define postmenopausal least 1 year , woman document infertility ( natural acquire ) . Male subject must agree , partner risk become pregnant , use medically accept , effective method contraception ( i.e . condom ) duration study ( maximum 7.5 month ) . Treatment stable dose either octreotide LAR lanreotide Autogel least 3 month immediately prior study entry , confirmation disease control treatment period ( documentation age adjust IGF 1 &lt; 1.3 x upper limit normal ( ULN ) , base local laboratory result , screen period ) . If subject receive treatment hypertension , dose stable least 1 month prior study entry . Subjects must willing able comply study restriction remain clinic require duration study period willing return clinic follow evaluation specify protocol . Has undergone radiotherapy within 2 year prior study entry . Has treat dopamine agonist and/or GH receptor antagonist undergone pituitary surgery within 3 month prior study entry . Is anticipated require pituitary surgery radiotherapy study . Has clinically significant hepatic abnormality and/or alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≥3 x ULN and/or alkaline phosphatase ( AP ) ≥2.5 x ULN and/or total bilirubin ≥1.5 x ULN and/or gammaglutamyl transpeptidase ( GGT ) ≥2.5 x ULN Screening period ( central laboratory result ) history finding somatostatin analogue ( SSTa ) treatment . Has clinically significant pancreatic abnormality and/or amylase and/or lipase ≥1.5 x ULN Screening period ( central laboratory result ) . Has significant renal abnormality and/or creatinine ≥1.5 x ULN screen period ( central laboratory result ) . Has uncontrolled diabetes ( glycosylated haemoglobin ( HbA1c ) ≥9 % , centrally assessed Screening period ) , diabetes treated insulin le 6 month prior study entry . Has know uncontrolled cardiovascular disease follow within 6 month Screening : ventricular atrial dysrhythmia ≥grade 2 , bradycardia ≥grade 2 , electrocardiogram ( ECG ) QT interval correct ( QTc ) prolong ≥grade 2 , myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , hypertension adequately control current medication . Use hormone replacement therapy ( HRT ) oestrogens . Has symptomatic gallstones/ sludge Screening Visit echography ( local assessment ) OR asymptomatic echography show clear evidence impend inflammation localise mucosal thicken suggest subject high risk develop acute disease . Subjects asymptomatic gallstones/ sludge otherwise normal echography may enter discretion investigator . Has abnormal finding Screening period , medical condition ( ) laboratory finding , opinion investigator , might jeopardise subject 's safety . Has treat investigational medicinal product ( IMP ) prior first study visit without undergo washout period seven time elimination halflife investigational compound . Has know hypersensitivity test material related compound . Is likely require treatment study drug permit study protocol . Has history , know current , problem alcohol drug abuse . Has mental condition render him/her unable understand nature , scope possible consequence study , and/or evidence uncooperative attitude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>